RBC Capital lowered the firm’s price target on Inspire Medical (INSP) to $125 from $150 but keeps an Outperform rating on the shares. The company delivered a marginal Q3 beat on revenue, but significant beat on EPS on a low bar, the analyst tells investors in a research note. Inspire’s “early indication” of 10%-11% 2026 growth reflects a base case off which it can make room to beat/raise, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- DraftKings, Flutter downgraded: Wall Street’s top analyst calls
- Inspire Medical price target lowered to $135 from $150 at Piper Sandler
- Inspire Medical upgraded to Overweight from Equal Weight at Wells Fargo
- Inspire Medical Systems Reports Strong Q3 2025 Growth
- Inspire Medical Systems Reports Q3 2025 Financial Results